Evidence map›Paper›PMID 31671109›Full record

ArticlePloS one2019

BDNF, NT-3 and Trk receptor agonist monoclonal antibodies promote neuron survival, neurite extension, and synapse restoration in rat cochlea ex vivo models relevant for hidden hearing loss.

Stephanie Szobota, Pranav D Mathur, Sairey Siegel, KristenAnn Black, H Uri Saragovi, Alan C Foster

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06729632 (Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 1 pooled it
2.7field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06729632 narecruitingnot on this mapstarted 2024, after this paper: background citation

Non-Invasive System to Deliver Therapeutic Hypothermia for Protection Against Noise-Induced Hearing Loss

TypeinterventionalSponsorRestorear Devices LLCRan2024 to 2027Enrolled116ConditionsNoise Exposure, Noise-induced Hearing Loss, Noise, Adverse EffectArmsCold pack-delivered mild therapeutic hypothermia
3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Stephanie SzobotaOtonomy, Inc., San Diego, California, United States of America.ORCID 0000-0003-0288-368X
Pranav D MathurOtonomy, Inc., San Diego, California, United States of America.
Sairey SiegelOtonomy, Inc., San Diego, California, United States of America.
KristenAnn BlackOtonomy, Inc., San Diego, California, United States of America.
H Uri SaragoviLady Davis Institute-Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Alan C FosterOtonomy, Inc., San Diego, California, United States of America.
Otonomy (United States) · USJewish General Hospital · CA

Funding

CIHR
6 · The paper itself

Abstract

Neurotrophins and their mimetics are potential treatments for hearing disorders because of their trophic effects on spiral ganglion neurons (SGNs) whose connections to hair cells may be compromised in many forms of hearing loss. Studies in noise or ototoxin-exposed animals have shown that local delivery of NT-3 or BDNF has beneficial effects on SGNs and hearing. We evaluated several TrkB or TrkC monoclonal antibody agonists and small molecules, along with BDNF and NT-3, in rat cochlea ex vivo models. The TrkB agonists BDNF and a monoclonal antibody, M3, had the greatest effects on SGN survival, neurite outgrowth and branching. In organotypic cochlear explants, BDNF and M3 enhanced synapse formation between SGNs and inner hair cells and restored these connections after excitotoxin-induced synaptopathy. Loss of these synapses has recently been implicated in hidden hearing loss, a condition characterized by difficulty hearing speech in the presence of background noise. The unique profile of M3 revealed here warrants further investigation, and the broad activity profile of BDNF observed underpins its continued development as a hearing loss therapeutic.

Indexed as

AnimalsAntibodies, MonoclonalBrain-Derived Neurotrophic FactorCell LineCell SurvivalCochleaDisease Models, AnimalHearing LossHumansNeuritesRatsReceptor, trkASynapsesAntibodies, MonoclonalBrain-Derived Neurotrophic FactorReceptor, trkA

Identifiers

PMID31671109
PMCPMC6822712
OpenAlexW2984014483

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.